Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dexcom (DXCM) Tax Provisions (2016 - 2026)

Dexcom has reported Tax Provisions over the past 13 years, most recently at $70.0 million for Q1 2026.

  • Quarterly Tax Provisions rose 43.15% to $70.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $273.2 million through Mar 2026, up 39.67% year-over-year, with the annual reading at $252.1 million for FY2025, 89.83% up from the prior year.
  • Tax Provisions was $70.0 million for Q1 2026 at Dexcom, down from $73.4 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $119.7 million in Q3 2023 and troughed at -$61.2 million in Q1 2022.
  • The 5-year median for Tax Provisions is $44.3 million (2024), against an average of $39.6 million.
  • Year-over-year, Tax Provisions crashed 302.63% in 2022 and then skyrocketed 690.1% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $41.4 million in 2022, then crashed by 124.4% to -$10.1 million in 2023, then skyrocketed by 690.1% to $59.6 million in 2024, then grew by 23.15% to $73.4 million in 2025, then fell by 4.63% to $70.0 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Tax Provisions are $70.0 million (Q1 2026), $73.4 million (Q4 2025), and $68.5 million (Q3 2025).